(Q24203880)

4

object named as

G Peter Herbison

0 references

author name string

Priya Madhuvrata

1

0 references

June D Cody

2

0 references

Gaye Ellis

Cochrane Database of Systematic Reviews

3

0 references

publication date

18 January 2012

0 references

published in

0 references

cites work

Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of fesoterodine and tolterodine in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Impact of fesoterodine on quality of life: pooled data from two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Fesoterodine dose response in subjects with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine: a safe and effective treatment for older patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy of fesoterodine over 24 hours in subjects with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Solifenacin significantly improves all symptoms of overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Drugs for nocturia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Urinary, faecal and sexual dysfunction in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

An epidemiological survey of overactive bladder symptoms in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The patient with an overactive bladder--symptoms and quality-of-life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Economic considerations and outcome measurement in urge incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Bladder training for urinary incontinence in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Prevalence of urinary incontinence in Korean women:an epidemiologic survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Efficacy and tolerability of fesoterodine in women with overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

The prevalence of urinary dysfunction in Hong Kong Chinese women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Dose titration in clinical trials. An example using emepronium carrageenate in detrusor instability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Genitourinary dysfunction in a geriatric outpatient population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Emepronium carrageenate: clinical effects and urinary excretion in treatment of female urge incontinence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005429.PUB2

7 January 2021

10.1002/14651858.CD005429.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1038535

1038535

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference